For more than four decades, herpes has been managed with treatments developed in the 1980s and 1990s.
These therapies suppress symptoms, but they do not eliminate the virus, do not reliably prevent transmission, and do not address the long term burden of the disease.
For many years, innovation in this field remained largely stagnant.
Today, this is beginning to change.
Advances in next generation antivirals, as well as therapeutic and preventive vaccine approaches, are demonstrating real potential to significantly reduce viral activity, transmission, and overall disease burden.
In parallel, longer term research avenues, including gene based technologies, are being explored as potential paths toward more durable solutions.
The challenge is no longer the absence of scientific possibilities.
The challenge is transforming progress into reality through coordination, strategic advocacy, and acceleration.